Dr. Ashley Shoemaker, MD

NPI: 1356499438
Total Payments
$29,722
2024 Payments
$4,330
Companies
6
Transactions
21

Payment Breakdown by Category

Other$12,890 (43.4%)
Research$10,391 (35.0%)
Consulting$6,218 (20.9%)
Food & Beverage$223.47 (0.8%)

Payments by Nature

Nature of Payment Amount Transactions Share
Honoraria $12,890 9 43.4%
Unspecified $10,391 1 35.0%
Consulting Fee $6,218 9 20.9%
Food and Beverage $223.47 2 0.8%

Payments by Type

General
$19,331
20 transactions
Research
$10,391
1 transactions

Top Paying Companies

Company Total Records Latest Year
Rhythm Pharmaceuticals, Inc. $15,543 15 $0 (2024)
AstraZeneca UK Limited $10,391 1 $0 (2019)
Radius Health, Inc. $2,365 2 $0 (2021)
Chiesi USA, Inc. $1,200 1 $0 (2024)
Orexigen Therapeutics, Inc. $129.17 1 $0 (2017)
Medtronic MiniMed, Inc. $94.30 1 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2024 $4,330 6 Rhythm Pharmaceuticals, Inc. ($3,130)
2023 $1,600 2 Rhythm Pharmaceuticals, Inc. ($1,600)
2022 $8,338 6 Rhythm Pharmaceuticals, Inc. ($8,338)
2021 $4,840 4 Rhythm Pharmaceuticals, Inc. ($2,475)
2019 $10,391 1 AstraZeneca UK Limited ($10,391)
2017 $223.47 2 Orexigen Therapeutics, Inc. ($129.17)

All Payment Transactions

21 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
12/11/2024 Rhythm Pharmaceuticals, Inc. IMCIVREE (Drug) Honoraria Cash or cash equivalent $670.00 General
Category: Genetic Disease
11/20/2024 Rhythm Pharmaceuticals, Inc. IMCIVREE (Drug) Honoraria Cash or cash equivalent $670.00 General
Category: Genetic Disease
09/13/2024 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $670.00 General
05/01/2024 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $450.00 General
04/12/2024 Chiesi USA, Inc. MYALEPT (Drug) Honoraria Cash or cash equivalent $1,200.00 General
Category: GENERALIZED LIPODYSTROPHY
01/11/2024 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $670.00 General
07/01/2023 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $250.00 General
05/18/2023 Rhythm Pharmaceuticals, Inc. Honoraria Cash or cash equivalent $1,350.00 General
05/05/2022 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Honoraria Cash or cash equivalent $900.00 General
Category: Genetic Disease
04/20/2022 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Consulting Fee Cash or cash equivalent $225.00 General
Category: Genetic Disease
04/19/2022 Rhythm Pharmaceuticals, Inc. Honoraria Cash or cash equivalent $1,350.00 General
02/22/2022 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Honoraria Cash or cash equivalent $3,600.00 General
Category: Genetic Disease
02/16/2022 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Consulting Fee Cash or cash equivalent $237.50 General
Category: Genetic Disease
01/07/2022 Rhythm Pharmaceuticals, Inc. Imcivree (Drug) Honoraria Cash or cash equivalent $2,025.00 General
Category: Genetic Disease
11/25/2021 Rhythm Pharmaceuticals, Inc. Honoraria Cash or cash equivalent $1,125.00 General
10/14/2021 Radius Health, Inc. Consulting Fee Cash or cash equivalent $645.00 General
05/20/2021 Radius Health, Inc. Consulting Fee Cash or cash equivalent $1,720.00 General
04/01/2021 Rhythm Pharmaceuticals, Inc. Consulting Fee Cash or cash equivalent $1,350.00 General
01/11/2019 AstraZeneca UK Limited BYDUREON (Drug) Cash or cash equivalent $10,391.40 Research
Study: A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes • Category: Cardiovascular and Metabolism
11/07/2017 Orexigen Therapeutics, Inc. CONTRAVE (Drug) Food and Beverage In-kind items and services $129.17 General
Category: OBESITY
06/06/2017 Medtronic MiniMed, Inc. Minimed 670G System (Device) Food and Beverage In-kind items and services $94.30 General
Category: Durable Pump

Research Studies & Clinical Trials

Study Name Company Amount Records
A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents with Type 2 Diabetes AstraZeneca UK Limited $10,391 1

About Dr. Ashley Shoemaker, MD

Dr. Ashley Shoemaker, MD is a Pediatric Endocrinology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356499438.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashley Shoemaker, MD has received a total of $29,722 in payments from pharmaceutical and medical device companies, with $4,330 received in 2024. These payments were reported across 21 transactions from 6 companies. The most common payment nature is "Honoraria" ($12,890).

Practice Information

  • Specialty Pediatric Endocrinology
  • Location Nashville, TN
  • Active Since 01/08/2007
  • Last Updated 03/24/2022
  • Taxonomy Code 2080P0205X
  • Entity Type Individual
  • NPI Number 1356499438

Products in Payments

  • BYDUREON (Drug) $10,391
  • Imcivree (Drug) $6,988
  • IMCIVREE (Drug) $1,340
  • MYALEPT (Drug) $1,200
  • CONTRAVE (Drug) $129.17
  • Minimed 670G System (Device) $94.30

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Endocrinology Doctors in Nashville